ArticleExperimental hematology & oncology2025

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial.

Eugenio Fernandez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.